Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

AbbVie : New Findings Reported from AbbVie Describe Advances in Biochemistry [Identification of novel resistance mechanisms to NAMPT inhibition via the de...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 06:11pm CEST

New Findings Reported from AbbVie Describe Advances in Biochemistry [Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD(+) biosynthesis pathway and NAMPT mutation]

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Chemistry - Biochemistry. According to news reporting out of North Chicago, Illinois, by NewsRx editors, research stated, "Cancer cells have an unusually high requirement for the central and intermediary metabolite nicotinamide adenine dinucleotide (NAD(+)), and NAD(+) depletion ultimately results in cell death. The rate limiting step within the NAD(+) salvage pathway required for converting nicotinamide to NAD(+) is catalyzed by nicotinamide phosphoribosyltransferase (NAMPT)."

Our news journalists obtained a quote from the research from AbbVie, "Targeting NAMPT has been investigated as an anti-cancer strategy, and several highly selective small molecule inhibitors have been found to potently inhibit NAMPT in cancer cells, resulting in NAD(+) depletion and cytotoxicity. To identify mechanisms that could cause resistance to NAMPT inhibitor treatment, we generated a human fibrosarcoma cell line refractory to the highly potent and selective NAMPT small molecule inhibitor, GMX1778. We uncovered novel and unexpected mechanisms of resistance including significantly increased expression of quinolinate phosphoribosyl transferase (QPRT), a key enzyme in the de novo NAD(+) synthesis pathway. Additionally, exome sequencing of the NAMPT gene in the resistant cells identified a single heterozygous point mutation that was not present in the parental cell line. The combination of upregulation of the NAD(+) de novo synthesis pathway through QPRT over-expression and NAMPT mutation confers resistance to GMX1778, but the cells are only partially resistant to next-generation NAMPT inhibitors."

According to the news editors, the research concluded: "The resistance mechanisms uncovered herein provide a potential avenue to continue exploration of next generation NAMPT inhibitors to treat neoplasms in the clinic."

For more information on this research see: Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD(+) biosynthesis pathway and NAMPT mutation. Biochemical and Biophysical Research Communications, 2017;491(3):681-686. Biochemical and Biophysical Research Communications can be contacted at: Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA. (Elsevier - www.elsevier.com; Biochemical and Biophysical Research Communications - www.journals.elsevier.com/biochemical-and-biophysical-research-communications/)

Our news journalists report that additional information may be obtained by contacting T.H. Huang, AbbVie Inc, North Chicago, IL 60064, United States. Additional authors for this research include L.T. Lam, K.L. Longenecker, M.H. Bui, K.B. Idler, K.B. Glaser, J.L. Wilsbacher, C. Tse, W.N. Pappano and J. Guo (see also Chemistry - Biochemistry).

Keywords for this news article include: North Chicago, Illinois, United States, North and Central America, Biochemistry, Chemistry, Oncology, Genetics, Cancer, AbbVie.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
03:30pABBVIE : Signs Humira Patent License with Mylan
DJ
02:06pABBVIE : Announces HUMIRA® (adalimumab) Patent License with Mylan
PR
07/16ABBVIE : Announces Submission of Supplemental New Drug Application to US FDA for..
AQ
07/14ABBVIE : Announces Submission Of Supplemental New Drug Application To US FDA For..
AQ
07/13ABBVIE : Provides Update on Phase 3 Study of Ibrutinib in Blood Cancer Diffuse L..
AQ
07/13ICER panel votes against elagolix for endometriosis
AQ
07/12ABBVIE : Studies from AbbVie Update Current Data on Alzheimer Disease (Digital t..
AQ
07/12ABBVIE : to Host Second-Quarter 2018 Earnings Conference Call
AQ
07/12ABBVIE : Announces Submission of Supplemental New Drug Application to US FDA for..
PU
07/12ABBVIE : Ex-dividend day for
FA
More news
News from SeekingAlpha
08:28aAbbVie out-licenses Humira patents to Mylan, biosimilar sales five years away.. 
07/1650 Is Nifty 
07/16DIVIDEND SENSEI'S PORTFOLIO UPDATE 4 : The 3 Essential Things All Investors Need.. 
07/16CVS responds to Trump Administration's request for info on now to lower drug .. 
07/16THE MILLENNIAL PORTFOLIO : Longer Than Long Term? 
Financials ($)
Sales 2018 32 939 M
EBIT 2018 14 433 M
Net income 2018 10 789 M
Debt 2018 29 248 M
Yield 2018 3,76%
P/E ratio 2018 13,93
P/E ratio 2019 12,43
EV / Sales 2018 5,54x
EV / Sales 2019 5,14x
Capitalization 153 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 113 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE-0.48%153 340
MERCK KGAA-4.60%12 965
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD104.00%11 648
KYOWA HAKKO KIRIN CO LTD0.95%11 279
JAZZ PHARMACEUTICALS PLC29.83%10 609
CONVATEC GROUP1.36%5 349